UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 3, 2010

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES x NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES x NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer x

Accelerated filer o

Non-accelerated filer o

Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES o NO x

At November 8, 2010, 8,009,951,287 shares of the issuer s voting common stock were outstanding.

FORM 10-Q

For the Quarter Ended

October 3, 2010

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three and nine months ended October 3, 2010, and September 27, 2009

Condensed Consolidated Balance Sheets as of October 3, 2010, and December 31, 2009

Condensed Consolidated Statements of Cash Flows for the nine months ended October 3, 2010, and September 27, 2009

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

22

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

23

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

57

Item 4.

Controls and Procedures

57

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

57

Item 1A.

Risk Factors

60

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

60

Item 3.

Defaults Upon Senior Securities

60

Item 5.

Other Information

60

Item 6.

Exhibits

61

Signature

62

PART I FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Nine Months Ended

(millions, except per common share data)

Oct. 3,

2010

Sept. 27,

2009

Oct. 3,

2010

Sept. 27,

2009

Revenues

16,171

11,621

50,248

33,472

Costs and expenses:

Cost of sales(a)

3,896

1,789

11,997

4,953

Selling, informational and administrative expenses(a)

4,633

3,282

13,876

9,508

Research and development expenses(a)

2,194

1,632

6,607

5,032

Amortization of intangible assets

1,156

594

3,972

1,755

Acquisition-related in-process research and development

charges

74

20

Restructuring charges and certain acquisition-related costs

499

193

2,091

1,206

Other deductions net

2,353

160

3,038

175

Income from continuing operations before provision for taxes on

income

1,440

3,971

8,593

10,823

Provision for taxes on income

564

1,092

3,198

2,952

Income from continuing operations

876

2,879

5,395

7,871

Discontinued operations net of tax

(5

(4

Net income before allocation to noncontrolling interests

871

2,881

5,391

7,877

Less: Net income attributable to noncontrolling interests

24

Net income attributable to Pfizer Inc.

866

2,878

5,367

7,868

Earnings per share basic:

Income from continuing operations attributable to Pfizer Inc.

common shareholders

0.11

0.43

0.67

1.17

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.11

0.43

0.67

1.17

Earnings per share diluted:

Income from continuing operations attributable to Pfizer Inc.

common shareholders

0.11

0.43

0.66

1.16

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.11

0.43

0.66

1.16

Weighted-average shares used to calculate earnings per common

share:

Basic

8,027

6,730

8,045

6,727

Diluted

8,057

6,762

8,079

6,758

Cash dividends paid per common share

0.18

0.16

0.54

0.64

(a)

Includes amortization of certain intangible assets, as disclosed in Note 10B. Goodwill and Other Intangible Assets: Other Intangible Assets.

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(millions of dollars)

Oct. 3,

2010

Dec. 31,

2009

(Unaudited)

Assets

Cash and cash equivalents

2,176

1,978

Short-term investments

20,288

23,991

Accounts receivable, less allowance for doubtful accounts

14,302

14,645

Short-term loans

774

1,195

Inventories

8,771

12,403

Current deferred tax assets and other current assets

7,284

6,962

Assets held for sale

494

496

Total current assets

54,089

61,670

Long-term investments and loans

10,344

13,122

Property, plant and equipment, less accumulated depreciation

19,450

22,780

Goodwill

43,787

42,376

Identifiable intangible assets, less accumulated amortization

58,627

68,015

Noncurrent deferred tax assets and other noncurrent assets

5,118

4,986

Total assets

191,415

212,949

Liabilities and Shareholders Equity

Short-term borrowings, including current portion of long-term debt

5,158

5,469

Accounts payable

3,206

4,370

Dividends payable

1,454

Income taxes payable

1,620

10,107

Accrued compensation and related items

1,853

2,242

Current deferred tax liabilities and other current liabilities

12,334

13,583

Total current liabilities

24,172

37,225

Long-term debt

39,010

43,193

Pension benefit obligations

5,196

6,392

Postretirement benefit obligations

3,258

3,243

Noncurrent deferred tax liabilities

16,940

17,839

Other taxes payable

8,578

9,000

Other noncurrent liabilities

6,193

5,611

Total liabilities

103,347

122,503

Preferred stock

54

61

Common stock

443

443

Additional paid-in capital

70,678

70,497

Employee benefit trusts

(8

(333

Treasury stock

(22,707

(21,632

Retained earnings

42,873

40,426

Accumulated other comprehensive (loss)/income

(3,698

552

Total Pfizer Inc. shareholders equity

87,635

90,014

Equity attributable to noncontrolling interests

433

432

Total shareholders equity

88,068

90,446

Total liabilities and shareholders equity

191,415

212,949

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Nine Months Ended

(millions of dollars)

Oct. 3,

2010

Sept. 27,

2009

Operating Activities:

Net income before allocation to noncontrolling interests

5,391

7,877

Adjustments to reconcile net income before allocation to noncontrolling interests to net

cash (used in)/provided by operating activities:

Depreciation and amortization

6,493

2,983

Share-based compensation expense

351

258

Asset write-offs and impairment charges

2,956

293

Benefit plan contributions (in excess of)/less than expense

(706

318

Deferred taxes from continuing operations

1,277

1,121

Other non-cash adjustments

(61

(248

Changes in assets and liabilities, net of acquisitions and divestitures

(10,505

(840

Net cash provided by operating activities

5,196

11,762

Investing Activities:

Purchases of property, plant and equipment

(966

(783

Purchases of short-term investments

(5,018

(57,148

Proceeds from redemptions and sales of short-term investments

9,493

31,747

Purchases of long-term investments

(2,674

(6,053

Proceeds from redemptions and sales of long-term investments

3,822

4,824

Other investing activities

496

508

Net cash provided by/(used in) investing activities

5,153

(26,905

Financing Activities:

Increase in short-term borrowings

4,686

28,473

Principal payments on short-term borrowings

(9,265

(29,976

Proceeds from issuances of long-term debt

23,997

Principal payments on long-term debt

(4

(910

Purchases of common stock

(1,000

Cash dividends paid

(4,544

(4,268

Other financing activities

32

(101

Net cash (used in)/provided by financing activities

(10,095

17,215

Effect of exchange-rate changes on cash and cash equivalents

(56

40

Net increase in cash and cash equivalents

198

2,112

Cash and cash equivalents at beginning of period

1,978

2,122

Cash and cash equivalents at end of period

2,176

4,234

Supplemental Cash Flow Information:

Cash paid during the period for:

Income taxes

11,519

1,748

Interest

2,039

723

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation

We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three-month and nine-month periods ended August 29, 2010, and August 23, 2009.

On October 15, 2009, we completed our acquisition of Wyeth and, commencing from the acquisition date, our financial statements include the assets, liabilities, operating results and cash flows of Wyeth. As a result, legacy Wyeth operations are reflected in our results of operations for the third-quarter and nine-month 2010 periods, but not for the third-quarter and nine-month 2009 periods. Also, legacy Wyeth cash flows are reflected for the nine-month period in 2010, but not for the nine-month period in 2009.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this document. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2009.

Note 2. Adoption of New Accounting Policies

The provisions of the following new accounting standards were adopted as of January 1, 2010 and did not have a significant impact on our consolidated financial statements:

An amendment to the recognition and measurement guidance for the transfers of financial assets.

An amendment to the guidelines for determining the primary beneficiary in a variable interest entity.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 3. Acquisition of Wyeth

On October 15, 2009 (the acquisition date), we acquired all of the outstanding equity of Wyeth in a cash-and-stock transaction, valued at the acquisition date at approximately $68 billion.

Recording of Assets Acquired and Liabilities Assumed

The following table summarizes the final amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as adjustments made in the first nine months of 2010 to the amounts initially recorded in 2009 (measurement period adjustments). The measurement period adjustments did not have a significant impact on our consolidated statements of income, balance sheets or cash flows in any period and, therefore, we have not retrospectively adjusted our financial statements.

(millions of dollars)

Amounts Recognized

as of Acquisition Date

(provisional)(a)

Measurement

Period

Adjustments

Amounts Recognized

as of Acquisition Date

(final)

Working capital, excluding inventories

16,342

37

16,379

Inventories(b)

8,388

(417

7,971

Property, plant and equipment

10,054

(216

9,838

Identifiable intangible assets, excluding

in-process research and development(b)

37,595

(1,533

36,062

In-process research and development(b)

14,918

(1,096

13,822

Other noncurrent assets

2,394

2,394

Long-term debt

(11,187

(11,187

Benefit obligations

(3,211

36

(3,175

Net tax accounts(c)

(24,773

1,058

(23,715

Other noncurrent liabilities

(1,908

(1,908

Total identifiable net assets

48,612

(2,131

46,481

Goodwill(d)

19,954

2,127

22,081

Net assets acquired

68,566

(4

68,562

Less: Amounts attributable to

noncontrolling interests

(330

(326

Total consideration transferred

68,236

68,236

(a)

As previously reported in Pfizer s 2009 Annual Report on Form 10-K.

(b)

These measurement period adjustments were recorded to reflect changes in the estimated fair value of certain intangible assets and inventories. These adjustments were made largely to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.

(c)

These measurement period adjustments primarily reflect the tax impact of the pre-tax measurement period adjustments. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.

(d)

Goodwill recognized as of the acquisition date totaled $19,172 million for our Biopharmaceutical segment and $2,909 million for our Diversified segment.

Note 4. Cost-Reduction Initiatives and Acquisition-Related Costs

We have incurred significant costs in connection with our cost-reduction initiatives (several programs initiated since 2005) and our acquisition of Wyeth on October 15, 2009.

Since the acquisition of Wyeth, our cost-reduction initiatives that were announced on January 26, 2009, but not completed as of December 31, 2009, have been incorporated into a comprehensive plan to integrate Wyeth s operations, generate cost savings and capture synergies across the combined company. We are focusing our efforts on achieving an appropriate cost structure for the combined company.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

We incurred the following costs in connection with all of our cost-reduction initiatives and the acquisition of Wyeth:

Three Months Ended

Nine Months Ended

(millions of dollars)

Oct. 3,

2010

Sept. 27,

2009

Oct. 3,

2010

Sept. 27,

2009

Transaction costs(a)

19

13

572

Integration costs(b)

231

113

650

242

Restructuring charges(c):

Employee termination costs

27

36

603

200

Asset impairments

174

17

677

108

Other

67

148

84

Restructuring charges and certain acquisition-related costs

499

193

2,091

1,206

Additional depreciation asset restructuring, recorded in our Condensed

Consolidated Statements of Income as follows(d):

Cost of sales

241

367

102

Selling, informational and administrative expenses

28

190

17

Research and development expenses

26

46

42

Total additional depreciation asset restructuring

295

10

603

161

Implementation costs(e)

70

249

Total

794

273

2,694

1,616

(a)

Transaction costs represent external costs directly related to our acquisition of Wyeth and primarily include expenditures for banking, legal, accounting and other similar services. Substantially all of the costs incurred in 2009 were fees related to a $22.5 billion bridge term loan credit agreement entered into with certain financial institutions on March 12, 2009 to partially fund our acquisition of Wyeth. The bridge term loan credit agreement was terminated in June 2009 as a result of our issuance of approximately $24.0 billion of senior unsecured notes in the first half of 2009.

(b)

Integration costs represent external, incremental costs directly related to integrating Wyeth and primarily include expenditures for consulting and systems integration.

(c)

Restructuring charges in 2010 are related to the integration of Wyeth. From the beginning of our cost-reduction initiatives in 2005 through October 3, 2010, Employee termination costs represent the expected reduction of the workforce by approximately 46,600 employees, mainly in manufacturing, sales and research, of which approximately 33,400 employees have been terminated as of October 3, 2010. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Asset impairments primarily include charges to write down property, plant and equipment to fair value. Other primarily includes costs to exit certain assets and activities.

(d)

Additional depreciation asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

(e)

Implementation costs in the three months and nine months ended September 27, 2009 represent external, incremental costs directly related to implementing cost-reduction initiatives prior to our acquisition of Wyeth, and primarily include expenditures related to system and process standardization and the expansion of shared services. For the three months ended September 27, 2009, implementation costs are included in Cost of sales ($16 million), Selling, informational and administrative expenses ($48 million), Research and development expenses ($5 million) and Other deductions net ($1 million). For the nine months ended September 27, 2009, implementation costs are included in Cost of sales ($42 million), Selling, informational and administrative expenses ($165 million), Research and development expenses ($36 million) and Other deductions net ($6 million).

The components of restructuring charges associated with all of our cost-reduction initiatives and the acquisition of Wyeth follow:

(millions of dollars)

Costs

Incurred

2005-2010

Activity through

Oct. 3, 2010(a)

Accrual as of

Oct. 3, 2010(b)

Employee termination costs

8,324

6,387

1,937

Asset impairments

2,129

2,129

Other

858

754

104

Total restructuring charges

11,311

9,270

2,041

(a)

Includes adjustments for foreign currency translation.

(b)

Included in Current deferred tax liabilities and other current liabilities ($1.6 billion) and Other noncurrent liabilities ($482 million).

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 5. Other (Income)/Deductions Net

The following table sets forth details related to amounts recorded in Other deductions net:

Three Months Ended

Nine Months Ended

(millions of dollars)

Oct. 3, 2010

Sept. 27, 2009

Oct. 3, 2010

Sept. 27, 2009

Interest income(a)

(100

(171

(297

(620

Interest expense(a)

428

369

1,339

769

Net interest expense

328

198

1,042

149

Royalty-related income

(158

(35

(395

(142

Net gain on asset disposals

(13

(40

(243

(81

Legal matters, net(b)

712

54

886

130

Certain asset impairment charges(c)

1,478

1,710

96

Other, net

(23

38

23

Other deductions net

2,353

160

3,038

175

(a)

Interest expense increased in 2010 due to our issuance of $13.5 billion of senior unsecured notes on March 24, 2009 and approximately $10.5 billion of senior unsecured notes on June 3, 2009, primarily related to the acquisition of Wyeth as well as the addition of legacy Wyeth debt. Interest income decreased in 2010 due to lower interest rates coupled with lower average investment balances.

(b)

Legal matters, net in the three-month and nine-month periods ended October 3, 2010 includes an additional $701 million charge for asbestos litigation related to our wholly owned subsidiary, Quigley Company, Inc.

(c)

The asset impairment charges in the three-month and nine-month periods ended October 3, 2010 are primarily related to intangible assets acquired as part of our acquisition of Wyeth, including IPR&D assets, Brands and, to a lesser extent, Developed Technology Rights. See also Note 3. Acquisition of Wyeth and Note 10B. Goodwill and Other Intangible Assets: Other Intangible Assets. The impairment charges result from our current estimate of the fair value of these assets, based upon updated forecasts, compared with their assigned fair values as of the Wyeth acquisition date, October 15, 2009. The fair value of acquired identifiable intangible assets generally is determined using an income approach that starts with a forecast of all of the expected future net cash flows associated with the asset which are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. Our updated forecasts of net cash flows for the impaired assets, reflect, among other things the following: for IPR&D assets, the impact of changes to the development programs, the projected development and regulatory timeframes and the risk associated with these assets; for Brand assets, the current competitive environment and planned investment support; and, for Developed Technology Rights, an increased competitive environment. Of these amounts, in the third quarter of 2010, about $900 million related to our Biopharmaceutical segment and $600 million related to our Diversified segment. The nine-month period of 2010 also included another $200 million in impairments related to our Biopharmaceutical segment.

Note 6. Taxes on Income

Our effective tax rate for continuing operations was 39.2% for the third quarter of 2010, compared to 27.5% for the third quarter of 2009, and 37.2% for the first nine months of 2010, compared to 27.3% for the first nine months of 2009. The higher tax rates in the third quarter and first nine months of 2010 are primarily the result of:

higher expenses incurred as a result of our acquisition of Wyeth, and the mix of jurisdictions in which those expenses were incurred;

the expiration of the U.S. research and development tax credit; and

the non-recurrence of a tax benefit of $174 million that was recorded in the third quarter of 2009 related to the final resolution of a previously disclosed settlement which resulted in the receipt of information that raised our assessment of the likelihood of prevailing on the technical merits of our tax position;

partially offset by:

the tax benefit associated with the charge incurred for asbestos litigation discussed in Note 5. Other (Income)Deductions Net.

The effective tax rate for the first nine months of 2010 was additionally impacted by the write-off of the deferred tax asset of approximately $270 million related to the Medicare Part D subsidy for retiree prescription drug coverage, resulting from changes in the U.S. healthcare legislation enacted in March 2010 concerning the tax treatment of that subsidy, effective for tax years beginning after December 31, 2012, offset by $460 million in tax benefits for the resolution of certain tax positions pertaining to prior years with various foreign tax authorities.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 7. Comprehensive Income

The components of comprehensive income follow:

Three Months Ended

Nine Months Ended

(millions of dollars)

Oct. 3,

2010

Sept. 27,

2009

Oct. 3,

2010

Sept. 27,

2009

Net income before allocation to noncontrolling interests

871

2,881

5,391

7,877

Other comprehensive income/(loss):

Currency translation adjustment and other

786

599

(4,105

2,853

Net unrealized losses on derivative financial instruments

(59

(43

(300

(210

Net unrealized gains/(losses) on available-for-sale securities

26

86

(86

312

Benefit plan adjustments

(45

(459

239

(282

Total other comprehensive income/(loss)

708

183

(4,252

2,673

Total comprehensive income before allocation to

noncontrolling interests

1,579

3,064

1,139

10,550

Less: Comprehensive income/(loss) attributable to

noncontrolling interests

(3

23

11

Comprehensive income attributable to Pfizer Inc.

1,574

3,067

1,116

10,539

Note 8. Financial Instruments

A. Selected Financial Assets and Liabilities

Information about certain of our financial assets and liabilities follows:

(millions of dollars)

Oct. 3,

2010

Dec. 31,

2009

Selected financial assets measured at fair value on a recurring basis(a) :

Trading securities(b)

169

184

Available-for-sale debt securities(c)

27,558

32,338

Available-for-sale money market funds(d)

862